Patient burden associated with clinical trial participation continues to drive a gap between the number of trial patients needed and the number who give consent and participate. Trials typically require patient travel to hospitals or investigator sites, often 25 miles or more from the patient’s home. Decentralized and hybrid clinical trials aim to lessen patient burden by reducing practical barriers to trial participation thus improving patient access, recruitment and retention. Incorporating patient centric approaches can therefore be immensely beneficial.
To fully realize the value of decentralization, remote patient centric sampling for laboratory pharmacokinetic, safety and biomarker measurements must be considered. In this webinar, different approaches to bring sampling to the patient will be reviewed. The featured speakers will focus on innovative solutions in the pipeline and discuss considerations that must be taken into account when designing and validating a decentralized laboratory sampling approach.
Join this webinar to learn more about patient centric sampling and how decentralized and hybrid approaches bring clinical trials directly to the patient.
Stephanie Cape, PhD, Head of R&D, Scientific Affairs, Labcorp Drug Development
Stephanie Cape, PhD heads Research and Development within Scientific Affairs at Labcorp Drug Development. The Scientific Affairs team is focused on positioning the laboratories with technologies and expertise to support the rapidly evolving needs of pharmaceutical testing.
Over the past 12 years with Labcorp Drug Development, Dr. Cape has served in a variety of scientific leadership roles, been actively engaged in a number of industry groups and grown a particular interest in enabling new technologies. She has held multiple leadership positions within the American Association of Pharmaceutical Sciences, serves as a subject-matter expert for the Bioanalysis Zone, is a member of the Bioanalysis journal editorial board, sits on the advisory board for the Madison College biotechnology program and is an active contributor to the Global CRO Council. Dr. Cape is particularly engaged in patient centric sampling and contributes to the Global Patient Centric Sampling Interest Group as well as the AAPS Microsampling and Patient Centric Sampling team.
Dr. Cape has authored over 30 peer reviewed publications including four book chapters and contributed many posters and presentations. She received her BS in chemistry from University of IL- Urbana/Champaign in 2003 and her PhD in analytical chemistry from the University of Wisconsin- Madison in 2007.
Bradley Collier, PhD, Research and Development Scientist, Labcorp
Bradley Collier, PhD received his doctorate in biomedical engineering from Texas A&M University in 2013. Holding several research positions, he has contributed to the development of a variety of analytical and microfluidic biotechnologies. Since 2017, Dr. Collier has been working for Labcorp where he currently investigates various novel capillary blood microsampling solutions for clinical measurements.
Satya N. Narla, PhD, NRCC(CC), Associate Director, Safety Testing Department, Labcorp Drug Development
Satya Narla, PhD is Associate Director for the safety testing team at Labcorp Drug Development’s Indianapolis central laboratory site. She joined Labcorp in January 2016 as Senior Scientist in Immunology and was promoted to Associate Director of Operations for the Safety Testing Department in 2019. Dr. Narla received her PhD in clinical bio-analytical chemistry from Cleveland State University in 2013 and completed her post-doctoral training as clinical chemist at the Medical University of South Carolina in 2015 prior to joining Labcorp. In her current role she is responsible for overall operational and technical management of the Safety Testing Department, including routine chemistry, immunology, hematology and urinalysis testing areas.
Gregory Sommer, PhD, Technical Director, Research and Development, Labcorp
Greg Sommer, PhD serves as Technical Director of R&D at Labcorp, overseeing the design, validation and deployment of new decentralized liquid microsample collection technologies. Dr. Sommer joined Labcorp in 2021 following Labcorp’s acquisition of Sandstone Diagnostics, Inc. — a consumer healthcare and diagnostics technology company he co-founded in 2012. He received his PhD in Mechanical Engineering from the University of Michigan in 2008, and previously served as a Staff Scientist in Biodefense Technologies at Sandia National Laboratories from 2008-2012.
Who Should Attend?
- Biopharmaceutical Developers
- Chief Medical Officer
- Senior Medical Director
- Medical Director
- Clinical Development Director
- Research and Development Director
- Operational Director
- Senior Operational Director
- Clinical Director
- Senior Clinical Director
- Research Director
- Clinical Project Manager
- Diagnostics Director
- Clinical Scientist
- Clinical Development Lead
What You Will Learn
- Understand the importance of integrating decentralized clinical trials solutions in order to reduce patient burden
- Understand available patient centric microsampling devices and formats
- Understand key considerations and strategies for utilizing patient centric sampling in a clinical trial
Labcorp Drug Development
Labcorp Drug Development is a leading clinical research organization that provides pharmaceutical and biotech clients with vital information to accelerate innovations and improve patient health through our unparalleled drug development capabilities. Learn more about Labcorp Drug Development at www.drugdevelopment.labcorp.com or follow us on LinkedIn and Twitter @LabcorpDrugDev.